Vioxx judge declares mistrial

Share this article:
The judge in the first federal lawsuit against Merck's Vioxx has declared a mistrial, according to published reports.
The ruling came this morning after jurors remained deadlocked following 18 hours of deliberations over three days last week.
According to published reports, the jury resumed what was to be its fourth day of deliberations today, but within about 20 minutes, U.S. District Judge Eldon Fallon summoned the jurors and reminded them they had agreed to reach a verdict in a "reasonable time."
"It has now been a reasonable time. We cannot get a verdict," Fallon reportedly said, declaring a mistrial. Federal litigation requires a unanimous verdict.
The panel was reported to be at odds over whether Merck was liable in Richard "Dicky" Irvin's 2001 death and whether the company failed to issue safety warnings that the drug could have serious cardiovascular repercussions.
This latest outcome leaves Merck with a 1-and-1 record in state trials and an undecided in the first of four federal trials overseen by Fallon. The company is up against about 7,000 pending state and federal lawsuits and its liability has been estimated at up to $50 billion.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.